Atossa Genetics Inc. (NASDAQ:ATOS) is on recovery track with 185% gain from a 1-year low price of $0.8. The company lost -4.2% to attain the price of $2.28 on 6/6/2019. Throughout the recent session, the prices were hovering between $2.21 and $2.44. These shares are 294.74% off its target price of $9 and the current market capitalization stands at $20.86M. The recent change has given its price a -21.78% deficit over SMA 50 and -69.15% deficit over its 52-week high. The stock witnessed -22.18% declines, 57.24% gains and 65.22% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ATOS’s volatility during a week at 8.29% and during a month it has been found around 7.73%.

Atossa Genetics Inc. (ATOS) Top Holders

Institutional investors currently hold around $1 million or 3.3% in ATOS stock. Look at its top three institutional owners: Ahrens Investment Partners Llc owns $238 thousand in Atossa Genetics Inc., which represents roughly 1.14% of the company’s market cap and approximately 23.8% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 69,489 shares of the stock are valued at $165 thousand. The third largest holder is Geode Capital Management, Llc, which currently holds $113 thousand worth of this stock and that ownership represents nearly 0.54% of its market capitalization.

Atossa Genetics Inc. 13F Filings

At the end of March reporting period, 5 institutional holders increased their position in Atossa Genetics Inc. (NASDAQ:ATOS) by some 159,771 shares, 9 decreased positions by 652,144 and 6 held positions by -521,788. That puts total institutional holdings at 290,127 shares, according to SEC filings. The stock grabbed 2 new institutional investments totaling 126,200 shares while 7 institutional investors sold out their entire positions totaling 593,401 shares.

Atossa Genetics Inc. (NASDAQ:ATOS) Insider Trades

Multiple company employees have indulged in significant insider trading. Atossa Genetics Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO, Gen Counsel and Secretary Guse Kyle has acquired 10,000 shares of Atossa Genetics Inc. (ATOS) in the trading session dated Nov. 15, 2017. These shares are worth $3,400 and were traded at $0.34 each. The SEC filing shows that Remmel H. Lawrence performed a purchase of 2,500 shares. The Director added these shares by way of transaction on Apr. 17, 2017. The company’s shares were assimilated at $0.63 per share worth to an investment of some $1,575 to the account of Remmel H. Lawrence.

Director, Remmel H. Lawrence, purchased 100 common shares of Atossa Genetics Inc. (ATOS) in the open market. In a transaction dated Apr. 01, 2016, the shares were bought at an average price of $4.95, giving away a sum of $495. After this purchase, 727 common shares of ATOS are directly owned by the insider, with total stake valued at $1,657.

In the transaction dated Mar. 09, 2016, a great number of shares acquired came courtesy the Director, 10% Owner; Chen Shu-Chih added a total of 1,000 shares at an average price of $5.55, amounting to approximately $5,550. The insider now directly owns 289,889 shares worth $660,947.

Atossa Genetics Inc. (ATOS) Analyst Guide

Not many analysts have released their opinion on Atossa Genetics Inc. (NASDAQ:ATOS), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].